LIFECORE BIOMEDICAL, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables
LIFECORE BIOMEDICAL, INC. (LFCR) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables of $7.06 million as of 2012-12-23, per its 10-Q filed 2013-09-26.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables · last filed 2014-03-28
- 2012-12-23: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $7.06M.
- 2012-04-23: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables $7.06M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables |
|---|---|
| 2012-12-23 | $7.06M 10-Q · filed 2013-09-26 |
| 2012-04-23 | $7.06M 10-Q · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |